336 research outputs found
Absorption and cutaneous deposition of yellow pigment in male and female broilers in response to different levels of xanthophylls from Tagetes erecta
To determine the saturation point of absorption and cutaneous deposition of yellow xanthophylls (XA) in broilers, two hundred and sixteen Ross 308 chickens (108 males and 108 females) were sorted by sex and randomly assigned to 6 dietary treatments containing 6 replications of 6 birds each. Treatments consisted of increasing levels of xanthophylls from Aztec marigold flower (Tagetes erecta) (65, 92, 119, 146, 173, and 200 ppm). Weight gain, feed consumption, and feed conversion were measuredweekly. Plasma pigment levels and skin yellowness in live birds were measured twice per week. Growth performance was analysed through ANOVA for a 6X2 factorial arrangement, where the first factor was the XA adding at six levels, and the second factor was sex at two levels. Pigment plasma concentration and skin yellowness were fitted into a multiple linear regression model. Results indicated that the highest levels of plasma xanthophylls and skin yellowness were found after 28 d of feeding. Skin yellowness increased by 2.24 b* for every d of xanthophylls consumption. In the females, skin yellowness was 1.35 b* higher than in the males. Increasing dietary xanthophylls by 10 ppm was reflected in 0.83 b* of increase in skin yellowness
Personality in patients with migraine evaluated with the "Temperament and Character Inventory"
The objective of this study was to assess the personality profile of a sample of Mexican patients with migraine using the Temperament and Character Inventory (TCI). A cross-sectional study was performed including adult migraine patients identified from the outpatient neurology clinics of two large teaching hospitals in Mexico City. Patients were asked to voluntarily participate in the study. A physician conducted a standardised diagnostic interview adhering to the criteria of the International Headache Society (IHS). Patients were interviewed and administered the TCI. We used two healthy controls groups and a third group of non-migraine pain controls. One hundred and fortytwo subjects with migraine, 108 healthy blood donors, 269 young healthy controls and 30 patients with non-migraine pain (NMP) were included in the study. Patients with migraine had higher scores in the dimension harm avoidance (HA) and all its sub-dimensions (p<0.05) than healthy patients. Patients with non-migraine pain had high scores in HA and low scores in novelty seeking, self-directedness and cooperativeness. Blood donors had high scores in the following subdimensions: HA1, HA4 and C3 (Cooperativeness). Personality features consistent with migraine are avoidance, rigidity, reserve and obsessivity. Our study shows that patients with chronic pain share some of the personality features of patients with migraine but their TCI profile could be indicative of cluster C avoidant personality. Blood donors were shown to have more energy, with a tendency to help other people and be more optimistic. The results support serotoninergic involvement as explaining the physiopathology of migraine
Diagnostico de intemperismo en la catedral de puebla
This paper presents a physicochemical approach to diagnose basalt weathering at Cathedral of Puebla facade, building located at downtown Puebla, which was built in the XVII century and has the particularity of having three sides exposed to the action of rain, wind and sun. Applied methodology included physical inspection of the building, collection of weathered samples, which were grounded, mixed with distilled water to prepare an analytical sample, determined physicochemical parameters allowed to discriminate which anions are causing basalt weathering.
Immunohistochemical distribution of secretagogin in the mouse brain
Introduction: Calcium is essential for the correct functioning of the central nervous system, and calcium-binding proteins help to finely regulate its concentration. Whereas some calcium-binding proteins such as calmodulin are ubiquitous and are present in many cell types, others such as calbindin, calretinin, and parvalbumin are expressed in specific neuronal populations. Secretagogin belongs to this latter group and its distribution throughout the brain is only partially known. In the present work, the distribution of secretagogin-immunopositive cells was studied in the entire brain of healthy adult mice.
Methods: Adult male C57BL/DBA mice aged between 5 and 7 months were used. Their whole brain was sectioned and used for immunohistochemistry. Specific neural populations were observed in different zones and nuclei identified according to Paxinos mouse brain atlas.
Results: Labelled cells were found with a Golgi-like staining, allowing an excellent characterization of their dendritic and axonal arborizations. Many secretagogin-positive cells were observed along different encephalic regions, especially in the olfactory bulb, basal ganglia, and hypothalamus. Immunostained populations were very heterogenous in both size and distribution, as some nuclei presented labelling in their entire extension, but in others, only scattered cells were present.
Discussion: Secretagogin can provide a more complete vision of calcium-buffering mechanisms in the brain, and can be a useful neuronal marker in different brain areas for specific populations.This work was supported by the Ministry of Economy, Industry and Competitiveness (MINECO) (SAF2016-79668- R to EW), the Ministry of Science and Innovation (PID2019- 106943RB-I00 to EW), the Ministry of Universities (MIU) (FPU20/03457 to PT), the Regional Government of Castile and Leon (SA178U13 to EW; EDU/556/2019 to LP-R), the Centre for Regenerative Medicine and Cell Therapy of Castile and Leon (EW), and the University of Salamanca (EW)
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.
Background: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2.
Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte- grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal- ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed.
Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1).
Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ- uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Background
We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015.
Methods
The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility.
Results
The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy.
Conclusions
Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals
Associations of iron metabolism genes with blood manganese levels: a population-based study with validation data from animal models
<p>Abstract</p> <p>Background</p> <p>Given mounting evidence for adverse effects from excess manganese exposure, it is critical to understand host factors, such as genetics, that affect manganese metabolism.</p> <p>Methods</p> <p>Archived blood samples, collected from 332 Mexican women at delivery, were analyzed for manganese. We evaluated associations of manganese with functional variants in three candidate iron metabolism genes: <it>HFE </it>[hemochromatosis], <it>TF </it>[transferrin], and <it>ALAD </it>[δ-aminolevulinic acid dehydratase]. We used a knockout mouse model to parallel our significant results as a novel method of validating the observed associations between genotype and blood manganese in our epidemiologic data.</p> <p>Results</p> <p>Percentage of participants carrying at least one copy of <it>HFE C282Y</it>, <it>HFE H63D</it>, <it>TF P570S</it>, and <it>ALAD K59N </it>variant alleles was 2.4%, 17.7%, 20.1%, and 6.4%, respectively. Percentage carrying at least one copy of either <it>C282Y </it>or <it>H63D </it>allele in <it>HFE </it>gene was 19.6%. Geometric mean (geometric standard deviation) manganese concentrations were 17.0 (1.5) μg/l. Women with any <it>HFE </it>variant allele had 12% lower blood manganese concentrations than women with no variant alleles (β = -0.12 [95% CI = -0.23 to -0.01]). <it>TF </it>and <it>ALAD </it>variants were not significant predictors of blood manganese. In animal models, <it>Hfe</it><sup>-/- </sup>mice displayed a significant reduction in blood manganese compared with <it>Hfe</it><sup>+/+ </sup>mice, replicating the altered manganese metabolism found in our human research.</p> <p>Conclusions</p> <p>Our study suggests that genetic variants in iron metabolism genes may contribute to variability in manganese exposure by affecting manganese absorption, distribution, or excretion. Genetic background may be critical to consider in studies that rely on environmental manganese measurements.</p
Recent Progress and Next Steps for the MATHUSLA LLP Detector
We report on recent progress and next steps in the design of the proposed
MATHUSLA Long Lived Particle (LLP) detector for the HL-LHC as part of the
Snowmass 2021 process. Our understanding of backgrounds has greatly improved,
aided by detailed simulation studies, and significant R&D has been performed on
designing the scintillator detectors and understanding their performance. The
collaboration is on track to complete a Technical Design Report, and there are
many opportunities for interested new members to contribute towards the goal of
designing and constructing MATHUSLA in time for HL-LHC collisions, which would
increase the sensitivity to a large variety of highly motivated LLP signals by
orders of magnitude.Comment: Contribution to Snowmass 2021 (EF09, EF10, IF6, IF9), 18 pages, 12
figures. v2: included additional endorser
- …